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Hepatitis virus infections affect a large proportion of the global population. The host
responds rapidly to viral infection by orchestrating a variety of cellular machineries, in
particular, the mitochondrial compartment. Mitochondria actively regulate viral
infections through modulation of the cellular innate immunity and reprogramming
of metabolism. In turn, hepatitis viruses are able to modulate the morphodynamics
and functions of mitochondria, but the mode of actions are distinct with respect to
different types of hepatitis viruses. The resulting mutual interactions between viruses
and mitochondria partially explain the clinical presentation of viral hepatitis, influence
the response to antiviral treatment, and offer rational avenues for novel therapy. In
this review, we aim to consider in depth the multifaceted interactions of mitochondria
with hepatitis virus infections and emphasize the implications for understanding path-
ogenesis and advancing therapeutic development.
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Hepatitis or liver inflammation is one of the most common liver dis-
eases that imposes a heavy global health burden.1,2 Acute hepatitis
is either self‐resolving or develops into chronic hepatitis and subse-
quently progresses to cirrhosis or hepatocellular carcinoma (HCC).3
The main etiologies include infection, metabolism, and autoimmune‐- - - - - - - - - - - - - - - - - - - - - - - - - -
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philin D; CsA, cyclosporine Arelated causes. Viral infections including hepatitis A, B, C, D, and E
viruses (HAV, HBV, HCV, HDV, and HEV, respectively) are the leading
causes (Table 1).
Host cells rapidly respond to viral infection by orchestrating a
variety of cellular machineries. In particular, the mitochondrial com-
partment appears important in this respect and responds in various
ways, including by acting as scaffold on which several key antiviral
molecular machineries are converged.4 Mitochondria antiviral‐
signaling protein (MAVS) acts as an adaptor for transcription and
production of interferons (IFN), the most potent antiviral cytokines,
in response to viral infection. Interestingly, different hepatitis
viruses differentially interact with MAVS, resulting in enhancement
or antagonism of host antiviral defense.5 In parallel, mitochondrial- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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TABLE 1 Features of hepatitis virus infections
HAV HBV HCV HDV HEV
Size, nm 27‐32 42 55‐62 36‐43 27‐34
Genome +ssRNA Partially dsDNA +ssRNA −ssRNA +ssRNA
Incubation period, d 15‐45 30‐180 15‐160 30‐60 15‐60
Genome length, nt 7500 3200 9600 1700 7,00
Envelope No/quasi enveloped Yes Yes Yes No/quasi enveloped
Transmission Fecal‐oral Blood and other body fluids Blood Blood and other body fluids Fecal‐oral
Infection course Acute Acute; chronic Acute; chronic Acute; chronic Acute; chronic
Severity of hepatitis ± ++ + + ±
Liver cancer development No Yes Yes Yes Not clear
Vaccine Yes Yes No No Yes (in China only)
Treatment N/A Yes Yes No approved medicationa No approved medicationa
Abbreviations: ds, double‐stranded; FDA, Food and Drug Administration; N/A, not applicable; nt, nucleotide; ss, single‐stranded.
aFor HDV, no FDA approved medication is available. Peg‐IFN‐α is the only recommended therapy, but the efficacy is unsatisfactory. For HEV, no FDA
approved medication is available. Ribavirin has been used as off‐label treatment with good efficacy.
2 of 11 QU ET AL.DNA (mtDNA) is able to elicit innate immune response through
Toll‐like receptor 9 (TLR9) and stimulator of interferon genes
(STING) signaling.6 Finally, the release of citric acid cycle intermedi-
ates from the mitochondrial matrix into the cytosol following viral
infection also regulates host innate immunity.7 Together, these
mechanisms likely impact on the infection course, pathogenesis,
and the clinical outcome of IFN‐α treatment in hepatitis virus
infections.
The liver is a metabolic powerhouse, and accordingly hepato-
cytes contain abundant numbers of mitochondria to support the
energy requirement associated with high metabolic activity.8 Viruses
require energy and macromolecule building blocks from the host to
complete their life cycle but on the other hand can modulate the
host metabolic machineries.9 Hepatitis viruses are known to regu-
late the number, quality, and dynamics of mitochondria, resulting
in altered mitochondrial morphology and function.10 Accordingly,
morphological and functional alterations of mitochondria are com-
monly observed in liver tissues obtained from viral hepatitis
patients.11-13
Intriguingly, accumulating evidences have suggest that mitochon-
drial products serve as mediators of many cellular signaling pathways,
including inflammatory responses that are prominent features of viral
hepatitis. Adenosine 5'‐triphosphate (ATP), the primary carrier of
energy, plays pleiotropic roles in inflammation by acting as an extracel-
lular signaling molecule.14,15 HCV replication actively consumes
intracellular ATP.16 5‐Aminoimidazole‐4‐carboxamide ribonucleotide
(AICAR), an activator of ATP production, counteracts both HCV and
HEV infection.17,18 HBV infection decrease ATP levels in hepato-
cytes.19 Several other metabolites from mitochondria, in particular, cit-
rate and succinate, are implicated in the pathological processes of viral
hepatitis and cirrhosis.20,21 Given the complexity, whether it is asequential or causal relationship between mitochondrial alteration
and hepatitis remains unclear.2 | MITOCHONDRIAL DYSFUNCTION IN
VIRAL HEPATITIS PATIENTS
Mitochondrial dysfunction is associated with many common disor-
ders.22 It is a prominent feature of liver cell injury and is often seen
in patients with viral hepatitis. HBV and HCV infections are frequently
accompanied by mitochondrial dysfunction. In patients, HCV infection
results in morphological alteration of mitochondria, reduction in the
copy number, and oxidative‐damage–triggered mutations in the
genome of mtDNA.11-13,23 Interestingly, mitochondrial abnormalities
in HCV patients vary in a genotype‐dependent manner. Their
frequency is higher in genotype 1b than genotype 2a/c or 3a infection,
suggesting a greater intrinsic cytopathic effect of genotype 1b
HCV.11,24 The current direct‐acting antivirals are highly effective in
inhibiting HCV infection. However, whether mitochondrial dysfunc-
tion persists in patients after HCV eradication remains an interesting
question to be investigated. In HBV patients, a lower level of serum
mtDNA content is related to an increased risk of HCC development,
indicating that circulating mtDNA may be a potential noninvasive
marker of HCC risk.25 Extensive mitochondrial gene dysregulation
and global downregulation of mitochondrial function have been
observed in HBV‐specific CD8 T cells from patients with chronic
infection. Treatment with mitochondria‐targeted antioxidants restores
antiviral activity of these exhausted HBV‐specific CD8 T cells.26 Data
regarding the mitochondrial status in hepatitis A and E patients remain
limited, identifying a need for future research.
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HEPATITIS VIRUSES AND MITOCHONDRIAL
COMPARTMENTS
3.1 | Apoptosis in the pathogenesis of viral hepatitis
Accumulating evidence supports the role of liver cell apoptosis in the
pathogenesis of viral hepatitis.27 Although there are multiple modes
of programmed cell death, pyroptosis and apoptosis cascades through
the extrinsic and intrinsic pathways are the predominant forms for
viral hepatitis.28 The extrinsic signaling is activated via the cell surface
death receptors including TNFR1, TRAIL‐R1, and Fas. The intrinsic
pathway is mainly triggered by nonreceptor stimuli but characterized
by the permeabilization of the outer mitochondrial membrane. This
leads to the release of proapoptotic factors from the mitochondrial
intermembrane space into the cytosol.29 A recent study demonstrates
that the extrinsic and intrinsic apoptotic pathways activate pannexin‐1
to drive NLRP3 inflammasome assembly, which is involved in the
pathogenesis of viral hepatitis.30,31
The numbers of apoptotic hepatocytes in chronic hepatitis B and C
patients are small but higher than those in healthy individuals.32 It is
now generally accepted that cytotoxic T lymphocytes mediate the
immune clearance of hepatitis virus‐infected hepatocytes. Immune‐
mediated apoptosis plays an important role in liver damage and
pathogenesis.33 However, hepatitis viruses may also have direct
effects on apoptosis. The role of the HBV X gene product (HBx) in
hepatocyte apoptosis is multifaceted. Proapoptotic function of HBx
has been reported in hepatocytes of transgenic mice,34 whereas it also
blocks Fas‐induced apoptosis in liver cells.35 Similarly, HCV infection
enhances susceptibility to Fas‐mediated apoptosis,36 whereas several
HCV proteins (core, E1, E2, and NS proteins) inhibit TNF‐α‐mediated
apoptosis.37 Recently, HEV has been reported to induce hepatocyte
apoptosis via mitochondrial pathway in Mongolian gerbils.38 However,
the underlining interaction between apoptosis and HEV infection
remains largely obscure.
Cytochrome c, an essential component of the electron transport
chain (ETC) transferring electrons from complex III to complex IV,
plays a key role in the early events of mitochondria‐mediated apopto-
sis. Serum cytochrome c has been suggested as a potential new
marker for fulminant hepatitis in patients.39 During apoptosis,
cytochrome c is released from the mitochondrial intermembrane space
to induce caspase activation. HCV can induce,40 whereas HEV can
block the release of cytochrome c from mitochondria to cytosol
(Figure 1).41 The possible correlation between the amount of serum
cytochrome c and the severity of hepatitis should be further explored
for potential diagnostic relevance. Besides cytochrome c, mutual inter-
actions between caspase activation and viral infection have also been
observed.42 Several viruses express proteins that could be cleaved by
the caspase protease, resulting in inhibition of apoptosis.43,44 For
example, the HCV viral nonstructural protein 5A can be cleaved by
activated caspase, which subsequently translocates to nucleus to
enhance the transcription of several NF‐κB target genes to inhibitapoptosis.45 The protein from HEV ORF2 has different forms and
could translocate to the cell nucleus.46 However, whether ORF2 pro-
tein is cleaved by the host protease and whether it regulates apoptotic
pathway remain to be further studied. Taken together, apoptosis is
likely an important mechanism in pathogenesis of viral hepatitis. Hep-
atitis viruses can modulate apoptotic pathways at various levels. Thus,
detection and quantification of particular apoptosis‐related molecules
may be explored as potential biomarkers for disease diagnosis in viral
hepatitis patients.3.2 | MAVS and mtDNA‐mediated Innate Immune
Response
The early and non‐specific detection of hepatitis viruses is generally
through the recognition by pathogen‐associated molecular patterns
(PAMP) as innate immunity sensors. This leads to the activation of
downstream IFN signal pathway and subsequent production of the
ultimate antiviral effectors, interferon‐stimulated genes (ISG).47,48
MAVS, acting as an adaptor for transcription and production of
IFN, shows specific interactions with different hepatitis viruses.
HAV and HCV provoke a blockade in cell‐autonomous IFN produc-
tion by inducing proteolytic release of a part of the extra‐
mitochondrial domain of MAVS. This is clinically supported by the
presence of cleaved MAVS in the liver biopsies of HCV—but not
HBV‐infected patients.49-51 The HCV protease NS3/4A cleaves
MAVS off the mitochondria,52 whereas HAV uses a stable, catalyti-
cally active polyprotein processing intermediate to target MAVS for
proteolysis.49 Instead of directly provoking MAVS proteolysis, HEV
induces MAVS to form “prion‐like” polymers, producing a type III
IFN response (Figure 1). The sequestering of MAVS in morphologi-
cally altered mitochondria may explain the relatively poor response
to IFN treatment in the clinical management of HEV compared with
that in HCV‐infected patients.5 Thus, exploring drugs preventing
aggregation of MAVS on the outer membrane of mitochondria could
be potentially used as a combination with IFN to enhance the anti‐
HEV efficacy. HBV infection is another case altogether, and investi-
gation of liver biopsies from chronic HBV patients indicates the
absence of activated innate immune response.53 Thus, HBV is likely
invisible to pattern recognition receptors, and the role of MAVS may
not be prominent.
Because mtDNA contains remnants of bacterial nucleic acid
sequences and is methylated in a different way from nuclear DNA, it
resembles non‐self DNA and is thus easily to be degraded after trans-
ferring to the cytosol, leading to the activation of innate immune
system.54 mtDNA‐mediated immune activation involves TLR9 and
cGAS‐STING signaling pathways, which contribute to the clearance
of invading pathogens and provoke inflammasome activation,
interleukin‐1 production, and pyroptosis.55,56 Because of bidirectional
transcription, mtDNA is capable of generating overlapped transcripts.
These formed long double‐stranded RNA structures that engage in
MDA5‐mediated antiviral signaling to trigger a type I IFN response.57
Clinically, IFN treatment in HCV patients significantly decreases the
FIGURE 1 The mutual interactions of the mitochondrial compartment with hepatitis viruses and the consequences on the infections. Hepatitis
viruses differentially modulate mitochondria antiviral‐signaling protein (MAVS) signaling. HAV and HCV cleave, while HEV induces MAVS
aggregation. These interactions with MAVS result in enhancement or antagonism of innate immune response. Hepatitis viruses either induce or
block the mitochondrial permeability transition pore (MPTP) opening, regulating the release of mitochondrial contents such as mitochondrial DNA
(mtDNA) fragment or adenosine 5'‐triphosphate (ATP), which then lead to antiviral defense. mtDNA that are not completely degraded are able to
enter the endocytic pathway through mitochondria‐derived vesicles, which engage Toll‐like receptor 9 (TLR9) in lysosomes and lead to the
activation of the NF‐κB signaling and interferons (IFN) production. Sustained apoptosis caused by hepatitis virus infection triggers damage of
membrane integrity, resulting in the liberation of mitochondrial contents into the extracellular milieu
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mtDNA copy numbers in peripheral leukocytes.12,58 Moreover,
mtDNA was reported to mediate IFN response.59 Even though hepa-
tocytes contain hundreds of copies of mtDNA, it is possible that the
combination of mtDNA deletions and point mutations, together with
mtDNA strand breaks by increased reactive oxygen species (ROS),
could reach a threshold sufficient to induce mitochondrial dysfunction,
contributing to the pathogenesis of viral hepatitis. Very recently, it has
been reported that new mtDNA synthesis can activate the NLRP3
inflammasome.60 As described, activation of NLRP3 inflammasome is
closely related to the pathogenesis of chronic liver diseases, including
viral hepatitis.313.3 | Mitochondrial morphodynamics in response to
hepatitis virus infection
The mitochondrial life cycle entails frequent fusion (in which two
mitochondria form a single organelle) and fission (the division of one
mitochondrion into two daughter organelles) events.61 These two
opposing processes collaboratively control the number and size of
mitochondria and maintain cell homeostasis. Mitofusin‐1 (Mfn1),
mitofusin‐2 (Mfn2), and optic atrophy 1 (Opa1) are the key regulators
of fusion, whereas dynamin‐related protein 1 (Drp1) tightly modulates
fission (Figure 2A). A main reason for continual mitochondrial fission
and/or fusion is that it facilitates the degradation of damaged
FIGURE 2 Mitochondrial morphodynamics is differentially regulated by hepatitis viruses to modulate innate immune response. A, The
mitochondrial life cycle entails frequent fusion and fission events. Mitofusin‐1 (Mfn1), mitofusin‐2 (Mfn2), and optic atrophy 1 (Opa1) are the
key regulators of fusion, whereas dynamin‐related protein 1 (Drp1) and mitochondrial fission 1 protein (Fis1) modulate fission. HBV and HCV
induce fission, whereas HEV triggers fusion. B, Immunofluorescence staining of human liver cells infected with HEV showing the induction of
mitochondrial fusion. HEV capsid protein (red; anti‐ORF2), mitochondria (green; anti‐HSP60), and 4',6‐diamidino‐2‐phenylindole DAPI (blue). Cells
were visualized with 63× oil immersion lens at identical settings
QU ET AL. 5 of 11organelles by mitophagy, which is regulated by Parkin and Pink
proteins. It promotes mitochondrial turnover and prevents accumula-
tion of dysfunctional mitochondria. HCV and HBV infections promote
mitophagy.62,63 The role of mitophagy in other hepatitis viruses needs
to be further studied.
Upon infection, hepatitis viruses rearrange the intracellular micro-
environment, including the mitochondrial compartment.64 Mitochon-
drial fission has been frequently observed in HBV and HCV
infections.10,65 HCV promotes fission by inducing Drp1 phosphoryla-
tion.66 This correlates with oxidative stress, presenting as excessivelipid peroxidation and deficiency of tissue hepatocellular antioxidant
stores, which in turn contributes to steatosis that is highly prevalent
in HCV infection.67,68 In contrast, HEV is able to trigger mitochon-
drial fusion to promote viral replication (Figure 2B).69 Because
mitochondrial fission is the initial step of mitophagy, the differential
regulation of mitochondrial morphodynamics by HEV compared
with HCV may suggest a negative regulation of mitophagy during
its propagation.
The fission and fusion processes in hepatocytes are responsible for
the exchange and reallocation of mitochondrial contents including
6 of 11 QU ET AL.mtDNA. Inhibition of mitochondrial fusion is related to mtDNA deple-
tion.70 Importantly, the equilibrium between fission and fusion is
crucial for stabilizing mtDNA copy number and maintaining healthy
liver function.71 Hence, modulation of mitochondrial morphodynamics
could potentially affect virus‐induced liver dysfunction.
In addition, morphodynamics also regulates innate immunity by
affecting the distribution of MAVS on the mitochondrial outer
membrane. As reorganization of MAVS spatial distribution is a key
event in IFN production in response to viral infection, such spatial
reorganization has important consequences. Mitochondrial fusion pro-
motes, whereas fission inhibits, RIG‐I‐like receptor (RLR) signaling.
Fibroblasts lacking mitofusin proteins produce less IFN and pro‐
inflammatory cytokines upon viral infection.72,73 Small molecules, such
as mitochondrial division inhibitor 1 (Mdivi1) that inhibits Drp1 activ-
ity, have been developed.74 Hence, the effects of these agents on
different hepatitis viruses are interesting be investigated.3.4 | The role of the mitochondrial electron
transport chain
Mitochondrial ETC consists of a series of complexes that transfer elec-
trons from donors to acceptors via redox coupled with the transfer of
protons across a membrane. It is the site for oxidative phosphorylation
and generation of ATP. Mitochondrial morphodynamics can regulate
the respiratory rate.75 Fused mitochondria enhance, whereas mito-
chondrial fission decrease, respiratory function. Thus, changing the
dynamics of mitochondrial fission and fusion influences mitochondrial
function and constitutes an evident target for viruses to corrupt
mitochondria‐mediated innate immunity. Hepatitis viruses actively
interact with the ETC; for example, HBx protein down‐regulates ETC
activity.76 HCV replication inhibits ETC and so the production of
ATP.77 By profiling the role of different ETC complexes, complex III
was found to support HEV replication.18
During cellular respiration, byproducts like ROS are produced
under stressed conditions.78 Increased ROS production is associated
with liver injury and the pathogenesis of viral hepatitis.79 Furthermore,
ROS production is involved in various cellular signaling pathways,
including those mediating immune responses. ROS can induce aggre-
gation of MAVS on mitochondrial outer membrane to initiate IFN
response. Cells with reduced ETC activity are impaired with produc-
tion of IFNs and proinflammatory cytokines during viral infection.80
In contrast, increased ROS production counteracts HCV replication.81
Thus, the ETC emerges as a primary target for viral infection, although
hepatitis viruses likely target its functionality indirectly, for instance,
by modifying mitochondrial morphodynamics.3.5 | Mitochondrial permeability transition pore and
hepatitis viruses
Mitochondria actively communicate with the cytosol and nuclear com-
partments. The signals involved are mediated through proteins located
on the mitochondrial membrane, including the mitochondrialpermeability transition pore (MPTP). Mitochondrial contents can
escape from the mitochondrial matrix during MPTP opening.82,83
The products related to the action of ETC, such as ATP and cyto-
chrome c, are transferred through MPTP to cytosol to exert biological
functions. MPTP is composed of voltage‐dependent anion channel
(VDAC) in the outer mitochondrial membrane, the adenine nucleotide
translocator (ANT) in the inner mitochondrial membrane, and
cyclophilin D (CypD) as its regulator in the matrix.
Hepatitis viruses have various interactions with MPTP. HBx pro-
tein has been shown to colocalize with VDAC, leading to alteration
of mitochondrial transmembrane potential. The 68‐117 region of
HBx interacts with mitochondria and is necessary for membrane per-
meabilization.84 HEV ORF3 protein sustains high levels of oligomeric
VDAC to preserve mitochondrial potential and membrane integrity,
thereby protecting infected cells from mitochondrial depolarization
and death.41 HBV and HCV core proteins provoke MPTP opening,
whereas HEV prevents such an event. In line with this, the MPTP
inhibitor cyclosporine A (CsA) inhibits HBV and HCV85-87 but pro-
motes HEV replication.18,88 As highlighted, the importance of mtDNA
in innate immunity, mtDNA fragments in fact are also released
through MPTP. Thus, targeting MPTP opening represents a potential
antiviral strategy.4 | THE IMPACT OF MITOCHONDRIAL
METABOLITES
Metabolites produced from the mitochondrial tricarboxylic acid cycle,
including citrate, succinate, fumarate, and acetyl‐CoA, are important
regulators of signaling transduction when released from the mitochon-
dria.56,89 Citrate synthase and succinate dehydrogenase are up‐
regulated in HBV‐infected cells, leading to elevation of the corre-
sponding metabolites such as fumarate and succinate.90 Succinate
has been recognized as an emerging signal transducer to activate
inflammatory pathways.7 An example is the increase in antigen‐
presenting capacity of dendritic cells if cytosolic succinate levels
increase.91 Thus, it is rational to suggest that such molecules may
modulate innate immunity in hepatocytes as well.92 HCV infection
has been related to elevated level of acetyl‐CoA, a metabolite that
participates in many biochemical reactions in protein, carbohydrate,
and lipid metabolism.93 It has been widely recognized that acetyl‐
CoA contributes to lysine acetylation by donating its acetyl group.94
Lysine modification controls many aspects of protein function and
provides an obvious mechanism as to how acetyl‐CoA can influence
cellular function. HBV replication is regulated by the acetylation status
of the cccDNA‐bound H3/H4 histones.95,96 Acetylation of retinoic
acid‐inducible gene I (RIG‐I) regulates its antiviral functions,97 and
RIG‐I is essential for sensing HAV,98 HBV,99 HCV,100 and HEV infec-
tions.101 Importantly, adequate cytosolic acetyl‐CoA level is required
for interferon‐γ (IFNγ) production.102 Other metabolites can inhibit
inflammatory responses. For example, lactate acts through the lactate
receptor to reduce hepatitis in mouse models.103 There is an increase
in lactate production in HCV‐infected cells, probably because the
QU ET AL. 7 of 11corruption of mitochondrial function provokes increased dependency
in the hepatocyte on glycolysis to support its energy needs.104 In
apparent agreement, targeting mitochondrial metabolism has been
proposed to prevent chronic neuroinflammation.105 This may bear
implications for treating neurologic diseases caused by HEV
infection.1065 | IMPLICATIONS FOR THERAPEUTIC
DEVELOPMENT
IFN‐α has been used in the clinic for decades to treat chronic HBV and
HCV infections. The effects of IFN on viral replication have been
linked to mitochondrial functions,107 but conversely, mitochondria
regulate antiviral IFN responses via MAVS or the production of ROS.
The development of direct‐acting antivirals (DAA), in particular, the
nucleoside/nucleotide analogues, constitutes a landmark in advancing
the treatment for viral hepatitis.108 Nucleoside/nucleotide analogues
can efficiently inhibit viral replication by inhibition of viral polymerase
activity.109 However, these drugs may exert off‐target effects by inhi-
bition of mitochondrial DNA polymerase, resulting in a reduction of
mtDNA copy number, although a minor reduction may not present a
clinically apparent phenotype.110,111 Fialuridine, a nucleoside analogue
investigated for treating HBV infection, caused five deaths from liver
failure associated with lactic acidosis and two required liver transplan-
tation.112 The toxicity is primary due to damaging mitochondria,
particularly in nerves, liver, skeletal, and cardiac muscle, as these tis-
sues contain many mitochondria.113 The degree of these side‐effects
limits development of this class of drugs, even though the antiviral
effect may be very promising.
Despite the launch of many antiviral drugs, new therapeutics are
still required for eliminating viral hepatitis. Unlike HCV, the persis-
tence of cccDNA prevents cure but only inhibits viral replication in
HBV patients.114 For HEV, besides supportive care and off‐label
treatment with ribavirin or IFN‐α for some cases, there is no proven
antiviral medication available. Mitochondria represent a viable target
for new therapeutic development. As mitochondrial dysfunction is
widely present in HBV patients, treatment with mitochondria‐targeted
antioxidants mitoquinone (MitoQ) and the piperidine‐nitroxide
MitoTempo can restore the antiviral activity of HBV‐specific CD8 T
cells.26 MitoQ is based on the delivery of a potent antioxidant with
targeted lipophilic cations that leads to accumulation up to several‐
hundred fold in mitochondria. It has been extensively studied and
demonstrated safety in humans.22,115,116 Because increased oxidative
stress and subsequent mitochondrial damage are the key mechanisms
causing pathogenesis in viral hepatitis, treatment with MitoQ can
decrease liver damage in HCV patients.115 It has also been shown to
attenuate liver fibrosis in mice.117
The mitochondrial ETC complexes have long been recognized as an
antiviral target.118 The complex I inhibitor, metformin, inhibits HBV
and HCV infections in experimental models,119,120 although
the effects in patients remain unclear. Complex III sustains HEV
replication and can be targeted by pharmacological inhibitors to inhibitviral replication in experimental models but requires further clinical
validation.18
Lastly, mitochondria‐mediated apoptosis is essential in the patho-
genesis of viral hepatitis; however, no optimal drug has been identified
to prevent or treat liver injury. In this respect, mitochondria‐targeted
antioxidants or caspase inhibitors, look promising, but require further
investigation.6 | CONCLUDING REMARKS
Liver cells are enriched in mitochondria that support the unique fea-
tures of hepatic metabolism but also orchestrate cell‐autonomous
antiviral immunity upon viral infection. Mitochondrial dysfunction
commonly occurs in viral hepatitis patients. This associates with dis-
ease progression from acute, chronic infection to cancer development.
Hepatitis viruses actively interact with the mitochondrial compartment
at various levels, including regulation of mitochondrial
morphodynamics, innate immune response, bioenergetics, and metab-
olism. The mode of actions of these interactions may differ among
the five major types of hepatitis viruses but are essential for under-
standing the pathogenesis, clinical outcome, and treatment response
in viral hepatitis patients.
The prominent role of mitochondria in contributing to pathology
has provided opportunities for therapeutic development against viral
hepatitis and prevention of liver cancer development. Several
mitochondrial‐related or targeted agents have been used in the clinic
or tested in clinical trials, including the complex I inhibitor metformin,
the MPTP inhibitor CsA, the NAD+ precursor nicotinamide mononu-
cleotide, the mitochondria‐targeted protective compounds MitoQ
and Bendavia, and the antioxidant coenzyme Q10. However, the
development and application of mitochondria‐related therapies remain
at their infancy. We propose to enhance the therapeutic development
by identifying and repurposing the existing FDA‐approved medica-
tions with mitochondria‐targeted properties. On the other hand,
dietary and herbal supplements121 and other new approaches122,123
should also be explored for their potential to modulate or restore
mitochondrial function.ACKNOWLEDGMENTS
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